Richard L. Cathomas

Chur, GR, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 175 publications

Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.

Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.

Journal: BJU international

Published: August 05, 2026

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 29, 2026

Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19.

Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 29, 2026

Prostate Cancer Incidence, Mortality, and Survival in Switzerland.

Prostate Cancer Incidence, Mortality, and Survival in Switzerland.

Journal: JAMA network open

Published: April 21, 2026

Oligometastatic hormone-sensitive prostate cancer: when can less be more?

Oligometastatic hormone-sensitive prostate cancer: when can less be more?

Journal: Urologie (Heidelberg, Germany)

Published: April 16, 2026

Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial.

Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial.

Journal: Cancer chemotherapy and pharmacology

Published: April 08, 2026

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Journal: European urology oncology

Published: January 18, 2026

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Journal: Prostate cancer and prostatic diseases

Published: January 03, 2026

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

Journal: European urology oncology

Published: November 17, 2025

Re: Microbial Cancer Immunotherapy Reprograms Hematopoiesis To Enhance Myeloid-driven Anti-tumor Immunity.

Re: Microbial Cancer Immunotherapy Reprograms Hematopoiesis To Enhance Myeloid-driven Anti-tumor Immunity.

Journal: European urology

Published: November 13, 2025

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.

Journal: Urologic oncology

Published: September 21, 2025

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

Journal: International journal of cancer

Published: July 03, 2025

Showing 1-12 of 175

Last Updated: 09/26/2026